TRENTON, N.J. (AP) — Generic drugmaker Sandoz announced plans Thursday to start selling an alternative to the EpiPen in the U.S. early next year.
The EpiPen injector is used to halt life-threatening allergic reactions to insect bites, nuts and other foods. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems.
Sandoz will sell prefilled syringes with the same medicine, the hormone epinephrine, under the name Symjepi. The price will be $250 for two, without insurance.
Two generic versions of EpiPen are sold in the U.S. for $300 a pair, including one from EpiPen seller Mylan. The company started selling its own generic after it was blasted for repeated hikes that pushed up its list price from $94 to $608 for a pair of brand-name EpiPens.
This image shows a new epinephrine prefilled syringe by Sandoz, Inc. Amid persistent shortages of EpiPens and other emergency autoinjectors that treat life-threatening allergic reactions, generic drugmaker Sandoz says that early next year it will launch a slightly cheaper rival in the U.S. Sandoz said Thursday, Dec. 6, 2018, that it plans to sell a pair of its generic autoinjectors for $250 without insurance. (Sandoz Inc. via AP)
What people pay varies, though, depending on insurance, discounts and the pharmacy.
Mylan’s injectors are made by a subsidiary of Pfizer, which is upgrading factories to fix quality problems. That resulted in production slowdowns. Pfizer said Thursday it’s shipping some injectors and expects to ship more in the coming months.
The shortages triggered temporary shortages of alternative products. As a result, U.S. regulators let some manufacturers extend expiration dates.
Sandoz, part of Novartis AG., will sell syringes with an adult dose made by Adamis Pharmaceuticals Corp. A children’s version will follow.
Israel’s Teva Pharmaceutical Industries began selling limited quantities of its new generic EpiPen in the U.S. last week.
___________________________________________________________
(Correction: The Associated Press originally reported erroneously that emergency allergy injector Auvi-Q was among products that had shortages because of an EpiPen shortage. Auvi-Q did not have shortages.)
